Login:
Share:
Email Facebook Twitter

SHP Share Chat - RSS Feed

Shire Share Chat (SHP)



Share Price: 2,925.00Bid: 2,923.00Ask: 2,925.00Change: 0.00 (0.00%)No Movement on Shire
Spread: 2.00Spread as %: 0.07%Open: 2,905.00High: 2,927.00Low: 2,893.00Yesterday’s Close: 2,925.00


Share Discussion for Shire (SHP)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


jange
Posts: 24,504
Off Topic
Opinion:No Opinion
Price:2,013.00
shp
27 Apr '12
Negative Points:
The successful roll out of Vyvanse is seen as crucial to maintain Shire's ADHD franchise. Any significant shortfall in the long term performance of Vyvanse may be detrimental to Shire.
Litigation risk remains in a number of potential products associated within the group's Human Genetic Therapies (HGT) business.
Continuing execution with respect to pipeline drug approvals is required to support longer-term performance forecasts.
 
jange
Posts: 24,504
Off Topic
Opinion:No Opinion
Price:2,013.00
shp
27 Apr '12
Financial Highlights:
Product sales increased by 24%.
Total revenues grew to $1.17 billion surpassing market expectations.
Net debt at 31 March 31 was $214 million (31December 31, 2011: $468 million), a reduction of$254 million, principally due to the strong free cash flow generated created in Q1 2012
jange
Posts: 24,504
Off Topic
Opinion:No Opinion
Price:2,013.00
shp
27 Apr '12
Interim results: Biopharmaceutical company Shire Plc saw first quarter net income grow to $238.4 million from $211.3 million in the same quarter a year earlier. Total revenues rose to $1.17 billion from $972.2 million last year, exceeding analyst projections. Recent acquisitions included the US biotech firm FerroKin BioSciences, which develops treatments for patients with iron overload, which Shire bought for approximately $325 million in March. This followed the purchase of the assets from vascular technology firm Pervasis Therapeutics. Vyvanse, Shire's top performing attention-deficit and hyperactivity drug revealed sales of $260 million in the first quarter, up 17% from the same period last year. Adderall, the group's attention-deficit-disorder drug, saw a 7% increase in sales to $111.4 million. Elsewhere, Shire also said research and development costs would grow by between 12% and 14% over the year with a minor dilution of gross margins to continue throughout the year, reflecting the impact of the group's $750million purchase of Advanced BioHealing last month. Management reiterated its expectation of good earnings growth in 2012.
jange
Posts: 24,504
Off Topic
Opinion:No Opinion
Price:2,013.00
shp
27 Apr '12
Shire plc is an international specialist pharmaceutical company which in-licenses and develops early stage projects for its own marketing in the major markets around the world. Registered in Jersey, headquartered in Ireland, it has a large operational base in the United Kingdom. Brands and products include Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.
Mr.Pepper
Posts: 1,319
Observation
Opinion:No Opinion
Price:2,019.00
mulledwine
23 Apr '12
Nomura initiated a buy on Bumi, target price 1400. And look where it is now. Duh! These 'analysts' make a f-art smell and sound reasonable by comparison.
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:2,020.00
SHP
5 Apr '12
Nomura has initiated buy on Shire, target price 2,300p.
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:2,158.00
SHP
16 Mar '12
Shire, the pharmaceutical company is also given the once over by Tempus. Quite a busy day for the company. It pulled out of an application to sell its Fabry disease treatment, Replagal, in the US after a misunderstanding with the Food and Drug Administration. It then announced a $100m purchase of FerroKin BioSciences, a company which makes treatments for excess iron following blood transfusions. The company had a storming 2011 and Tempus thinks despite a turbulent Thursday, the stock is worth buying on any weakness.
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:2,202.00
SHP
15 Mar '12
Shire's Specialty Pharmaceuticals Senior Vice President, Hematology, Ross
Murdoch says:

"There remains a significant unmet need for a once-a-day, oral iron chelator in
a convenient dosage form for the treatment of transfusional iron overload with
a better safety profile than currently available treatments(2). We believe
FBS0701 has the potential to meet that need. We hope to use our expertise in
hematology coupled with our proven ability to progress products through the
development pipeline to bring FBS0701 to the global marketplace. This
acquisition marks an important step for Shire in building a business that
serves the growing needs of specialty hematologists and their patients."

FerroKin BioSciences' key employees, including Founder and CEO, Dr. Hugh Young
Rienhoff, Jr. will provide consulting services to Shire during the transition
period. "An important factor for FerroKin BioSciences in agreeing to this
transaction was Shire's drive, capability and vision to bring new products to
the hematology market that promise to raise the standard of care for patients.
In Shire's hands, FBS0701 has greater potential to fulfill that promise," said
Dr. Rienhoff.

The closing of the acquisition is subject to customary conditions, including
(i) adoption of the Merger Agreement by a required proportion of FerroKin's
equityholders; (ii) holders of no more than 2% of FerroKin's capital stock
having exercised or being entitled to exercise appraisal rights under Delaware
law and (iii) the absence of a material adverse effect on FerroKin BioSciences
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:2,203.00
SHP
15 Mar '12
Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator
treatment

Dublin, Ireland - March 15, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the
global specialty biopharmaceutical company, announces that it has signed an
agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100
million, payable in cash at closing, plus potential post-closing milestone
payments of up to $225 million, depending upon the achievement of certain
clinical development, regulatory and net sales targets.

* A strategic step in building Shire's hematology business (which already
includes Xagrid and a growing development pipeline)

* Adds a differentiated product in development (iron chelator FBS0701), with
global rights, in a global market currently worth over $900 million and
growing(1)

* Serves chronic patient need for treatment of iron overload following
numerous blood transfusions. Excess iron in vital organs such as the liver
and heart increases the risk of organ failure and is the principal cause of
death in transfusion-dependent patients(2)

* Consistent with Shire strategy of developing and commercializing
differentiated specialist products prescribed by specialist physicians
(hematologists/ hematologist-oncologists) served by a small sales force

* FBS0701 will be developed to demonstrate clinical efficacy and an
attractive safety profile relative to currently approved chelating agents:

* Global filing planned for indications for Myelodysplastic Syndrome and
hemoglobinopathies initially

* Phase 2 studies underway with additional trials planned

* Potential launch as early as 2016
mulledwine
Posts: 35,667
Observation
Opinion:No Opinion
Price:2,203.00
SHP
15 Mar '12



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.